Login
Navigate Fool.com
Will ICLR beat
the market?

ICON plc (ADR) (NASDAQ: ICLR)

Community Rating: 4 Stars: Favorite

47.49 0.00 (0.00%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $0.00
Previous Close $47.49
Daily Range $0.00 - $0.00
52-Week Range $35.33 - $50.00
Market Cap $2.9B
P/E Ratio 24.86
Dividend (Yield) $0.00 (0.0%)
Volume 0
Average Daily Volume 423,241
Current FY EPS $2.37

How do you think ICLR
will perform against the market?

Top ICLR Bull/Bear Pitches

 

CellBlock9 (< 20)
Submitted January 11, 2013

S &amp;P 5 star

0 Replies Reply Report this Post
 

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches here!

News & Commentary Rss Feed

Is This Stock the Next Tax-Fleeing Takeout?

Icon Plc (ICLR) operates in the fast growing drug R&D industry and its tax friendly Irish address may make it an attractive acquisition target for larger peers like Quintiles (Q) or Covance (CVD)

Icon (ICLR) Shares Cross Above 200 DMA

Icon Breaks Below 200-Day Moving Average - Notable for ICLR

4 Disruptive Stocks Biotechs Depend On

Contract research organizations Quintiles (Q), Icon PLC (ICLR), Covance (CVD), and Parexel (PRXL) are redefining how biopharma discovers and develops new therapies.

S&P 500 chips away at major resistance

Worried About Obamacare? Invest in This Sector Instead

Looking for health-care exposure in your portfolio, but want to steer clear of the Obamacare debate? Then this little-known health-care industry could be the answer.

Why Selling CROs Like Parexel May Be Short-Sighted

Contract Researchers have taken it on the chin following Parexel's (PRXL) lackluster quarterly results. But that view might be short sighted given drug makers are increasingly turning to CROs to usher drugs through trials.

ICON Reports second quarter 2013 Revenue of $334 million, up 21% year on year, non-GAAP EPS of 43c a

ICON shareholders vote in favour of all resolutions at its Annual General Meeting

ICON Reports First Quarter 2013 Revenue of $317 Million, up 26% year on year and non-GAAP EPS of 36c

See More ICLR News...

Sector

Healthcare

Industry

Healthcare Information Services

ICON plc (ADR) (ICLR) Description

The Company is a contract research organization, providing clinical research and development services on a global basis to the pharmaceutical, biotechnology and medical device industries. Website: http://www.iconplc.com/

More details for ICON Jobs
ICON reviews from employees

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks